Testing ublituximab for treatment-resistant schizophrenia
Treatments studied
Part of Mental health clinical trials.
This trial tests an experimental drug, ublituximab, to see if it helps people with schizophrenia that hasn't gotten better with standard treatments. It may offer a new option for those who still have significant symptoms despite current therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of schizophrenia that hasn't responded well to treatment.
- You are currently taking antipsychotic medication as part of your usual care.
- Your schizophrenia symptoms are at a moderate to severe level, as measured by a standard scale.
- You are not currently taking clozapine.
- You do not have any other major mental health condition besides schizophrenia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This trial is testing a new medication that may reduce inflammation in the brain for people with schizophrenia. It focuses on those who have a specific immune marker, which might mean the medication could help with symptoms.
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.